BPC-157 Dosing Protocol: Ranges, Frequency, and Duration

What BPC-157 dosing protocols look like in practice

BPC-157 dosing protocols vary by prescriber, use case, and the animal literature being extrapolated from. There is no FDA-approved human dosing; the ranges below are from research protocols and practitioner reports. Your prescribing provider's instructions take precedence over any general reference.

Common dose ranges

The most commonly reported starting protocol is 250 mcg once daily. Some practitioners prefer twice-daily for acute injury in the first 2–4 weeks, then stepping down to once daily.

Why twice-daily doesn't mean double the effect

BPC-157 has a ~4-hour half-life. With once-daily dosing, the compound is effectively cleared within 20 hours — less than 3% remains by the next dose. Twice-daily dosing provides a second peak ~12 hours after the first, maintaining higher active levels during the day. Whether the second pulse provides meaningfully different outcomes than once-daily is not well established in human data.

The rationale for twice-daily in acute injury contexts: the tissue repair process is continuous, and maintaining active levels during both waking and sleeping periods may be advantageous during the acute phase. Once healing progresses and the acute phase passes, many protocols step down to once daily.

Protocol duration

Typical protocol durations from practitioner reports:

• Acute injury: 4–12 weeks, sometimes longer for significant musculoskeletal injuries. Protocol typically continues until injury resolution or plateau.
• GI applications: 4–8 weeks commonly reported; some practitioners run maintenance doses indefinitely for chronic GI conditions.
• General use / stacked with other compounds: Varies widely. Some practitioners cycle (8–12 weeks on, 4–8 weeks off); others run maintenance continuously.

Long-term safety data in humans is limited. Protocol duration is a clinical decision based on your use case and your provider's judgment.

Units to draw at common doses

For a 5 mg vial + 2 mL bac water (concentration: 2,500 mcg/mL):

For a different bac water volume or vial strength, use the reconstitution calculator to get the correct draw for your specific setup.

Fasting: not required for BPC-157

Unlike CJC-1295/Ipamorelin, BPC-157 does not require fasted-state injection. Its mechanism (NO signaling, VEGF, cytoprotection) is not insulin-dependent. Inject at whatever time fits your schedule — morning with other SubQ injections is common for convenience, but there is no pharmacological benefit to fasting.

Site rotation with daily dosing

Daily injection demands rotation. Injecting at the same site daily causes lipohypertrophy — fatty tissue buildup that reduces absorption. With a ~4-hour half-life and no accumulation, impaired absorption directly reduces active levels.

A 6-site rotation (left/right abdomen × 2 zones, left/right thigh) gives 6 days between returns to any single site. Log each injection site so you can track which sites have been used recently. See the injection site rotation guide for the full zone map.